Qiagen Q4 Earnings Call Highlights

Core Insights - Qiagen closed 2025 with fourth-quarter results exceeding expectations, demonstrating growth in key product lines and improved profitability despite a challenging macro environment for life science funding and capital spending [2] Financial Performance - For Q4 2025, Qiagen reported net sales of $540 million, a 1% increase at constant exchange rates (CER), surpassing the outlook for flat sales year-over-year. Adjusted diluted earnings per share (EPS) were $0.62 at CER, exceeding management's forecast of approximately $0.60 [3] - For the full year, Qiagen achieved net sales of $2.09 billion, reflecting a 5% increase at CER, aligning with the high end of the growth outlook of 4% to 5%. Adjusted diluted EPS rose to $2.40 at CER, which was $0.12 above the initial outlook and compared to $2.18 in 2024 [3][5] Growth Drivers - Qiagen's "growth pillars" generated combined sales of $1.49 billion at CER in 2025, an 8% increase at CER. These pillars include Sample Technologies, QuantiFERON, QIAstat-Dx, QIAcuity, and QIAGEN Digital Insights (QDI), positioning the company for at least $2 billion in combined growth-pillar sales by 2028 [4][5] Profitability and Cash Flow - The adjusted operating margin improved to 29.5%, an increase of 80 basis points. Operating cash flow reached $654 million, and the company returned over $1.1 billion to shareholders, including a $500 million synthetic repurchase [5] - Guidance for 2026 anticipates at least 5% sales growth (CER) and adjusted EPS of at least $2.50 [5]